Bristol Myers Squibb’s next-gen multiple myeloma drug mezigdomide cut the risk of disease progression or death for certain patients by 52% when added to a treatment regimen.
May 29, 2026 08:00 AM EDT
Bristol Myers details Phase 3 trial win for Pomalyst successor
Lei Lei Wu
News Reporter
Bristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of …
Bristol Myers unveils data for one of its next-gen blood cancer drugs
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
New pill offers hope for patients with incurable blood cancer
Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma
Mieloma multiplo: ecco la nuova indicazione di daratumumab | Libero Quotidiano.it
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
Mieloma multiplo: ecco la nuova indicazione di daratumumab - Il Quotidiano del Sud
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its…
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of…
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology…
About 6,200 people every year in the UK are diagnosed with multiple myeloma
Teclistamab improved PFS, OS in patients who had received up to three previous lines of therapy
di TMNewsmercoledì 27 maggio 20262' di letturaRoma, 22 mag. (askanews) - Una nuova combinazione con bortezomib, lenalidomide,…
